The lab will launch virtually first, before moving into a physical space early next year. Photo via Getty Images

A Houston-based global software development company has teamed up to create an innovation lab that will launch virtually before moving into a physical space early next year.

Softeq Development Corporation announced the creation of the Softeq Innovation Lab in partnership with the Massachusetts Institute of Technology's Integrated Design and Management program and Massachusetts-based Boundless Technology. The lab is directed at helping enterprise companies collaborate on the technologies of tomorrow, according to a news release.

"At the Softeq Innovation Lab, we recognize the importance of developing an incubator that goes beyond innovation theatre and are rolling up our sleeves to achieve transformative disruption in enterprise companies," says Christopher A. Howard, Softeq founder and CEO, in the release.

"The first wave of disruption was based in Silicon Valley," he continues. "The second wave of disruption is occurring in industries central to Houston's economy such as energy, health care, and financial services. With technology rewriting the playbooks for these industries, Houston is the perfect venue for our Innovation Lab to enable companies to thrive in this new age of disruption."

First up for the lab is a series of Boundless Bootcamps, which aims to connect participants to corporate disruptors, including David Rose of Warby Parker and MIT Media Lab.

"The city of Houston is at the center of a powerful convergence between industry, innovation and proven intrapreneurs," says Chuck Goldman, principal at Boundless Technology, in the release. "The Softeq Innovation Lab brings together entrepreneurs, corporations and 20X innovators who have achieved ROI of at least 20X and built billion-dollar businesses."

In addition to having access to MIT, Boundless, and Softeq's global networks, the participants will also receive an MIT IDM Certification from the nation's top engineering, design, and business program.

"I'm thrilled to bring our leadership and human-centered design program to Houston to help intrapreneurs drive breakthrough growth in leading organizations" says Matt Kressy, founding director MIT IDM, in the release.

For additional information or to find out more about how to get involved please visit the Softeq Innovation Lab's website.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.